PAUL M. KARPECKI
- Type
- Physician · Eye and Vision Services Providers / Optometrist
- Where
- LEXINGTON, KY
- NPI
- 1619910569
- Received
- $3,567,445 in 2,160 records, 2019 to 2025 ($3,564,402 general, $3,043 research); ownership interests with $61,740 invested
- As principal investigator
- $88,499 of research payments to others in 18 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 397 | $594,015 |
| 2024 | General payment | 373 | $519,797 |
| 2024 | Ownership or investment interest | 1 | $225 |
| 2023 | General payment | 266 | $458,819 |
| 2023 | Ownership or investment interest | 1 | $225 |
| 2022 | General payment | 271 | $444,990 |
| 2022 | Ownership or investment interest | 3 | $310 |
| 2022 | Research payment | 1 | $3,043 |
| 2021 | General payment | 261 | $528,809 |
| 2021 | Ownership or investment interest | 4 | $335 |
| 2020 | General payment | 207 | $473,532 |
| 2020 | Ownership or investment interest | 5 | $30,335 |
| 2019 | General payment | 367 | $544,436 |
| 2019 | Ownership or investment interest | 3 | $30,310 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 575 | $1,902,849 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 197 | $888,391 |
| Compensation for serving as faculty or as a speaker for a medical education program | 96 | $221,267 |
| Honoraria | 64 | $205,947 |
| Travel and Lodging | 420 | $139,070 |
| Ownership or investment interest | 17 | $61,740 |
| Food and Beverage | 754 | $58,380 |
| Acquisitions | 1 | $55,613 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 24 | $53,200 |
| Royalty or License | 1 | $32,898 |
| Education | 7 | $6,673 |
| Research payment | 1 | $3,043 |
| Gift | 2 | $59 |
| Entertainment | 1 | $50 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | Harrow Eye, LLC | $3,675 | Consulting Fee | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-12-23 | RxSight Inc | $3,000 | Consulting Fee | Cash or cash equivalent | RXSIGHT CONTACT LENS Device, OPHTHALMOLOGY | 2025 | |
| 2025-12-11 | Tarsus Pharmaceuticals, Inc. | $5,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-10 | Tarsus Pharmaceuticals, Inc. | $34 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-09 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-12-05 | Nordic Pharma, Inc. | $13,125 | Consulting Fee (7 payments) | Cash or cash equivalent | LACRIFILL Device, Opthalmology | 2025 | |
| 2025-12-05 | Sight Sciences, Inc. | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEARCARE SYSTEM Device, Ophthalmology | 2025 | |
| 2025-12-05 | Tarsus Pharmaceuticals, Inc. | $3 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-04 | Bausch & Lomb Americas Inc. | $4,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-12-04 | Tarsus Pharmaceuticals, Inc. | $152 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-03 | Tarsus Pharmaceuticals, Inc. | $572 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-03 | Tarsus Pharmaceuticals, Inc. | $176 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-03 | Tarsus Pharmaceuticals, Inc. | $134 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-03 | Tarsus Pharmaceuticals, Inc. | $99 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-03 | Tarsus Pharmaceuticals, Inc. | $46 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-03 | Tarsus Pharmaceuticals, Inc. | $25 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-03 | Tarsus Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-11-29 | Harrow Eye, LLC | $12,388 | Consulting Fee | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-29 | Harrow Eye, LLC | $2,975 | Consulting Fee | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-29 | Harrow Eye, LLC | $250 | Consulting Fee | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-25 | BIOTISSUE HOLDINGS INC. | $6,660 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-25 | RxSight Inc | $1,750 | Consulting Fee | Cash or cash equivalent | LIGHT ADJUSTABLE LENS (LAL) Device, OPHTHALMOLOGY | 2025 | |
| 2025-11-25 | Mallinckrodt Hospital Products Inc. | $655 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-21 | Mallinckrodt Hospital Products Inc. | $17 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-20 | Tarsus Pharmaceuticals, Inc. | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-11-20 | Bausch & Lomb Americas Inc. | $2,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Tarsus Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-11-19 | Tarsus Pharmaceuticals, Inc. | $3,125 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Tarsus Pharmaceuticals, Inc. | $2,500 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Tarsus Pharmaceuticals, Inc. | $1,250 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | Bausch & Lomb Americas Inc. | $337 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-11-17 | Bausch & Lomb Americas Inc. | $309 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-11-17 | Bausch & Lomb Americas Inc. | $102 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-11-14 | Harrow Eye, LLC | $82 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-13 | Mallinckrodt Hospital Products Inc. | $7,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-11-11 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-11-06 | Harrow Eye, LLC | $8,400 | Honoraria | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-06 | Harrow Eye, LLC | $671 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-06 | Harrow Eye, LLC | $249 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-06 | Harrow Eye, LLC | $170 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-06 | Harrow Eye, LLC | $114 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-11-05 | Tarsus Pharmaceuticals, Inc. | $2,187 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-04 | Tarsus Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-10-31 | Alcon Vision LLC | $34 | Food and Beverage | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-10-30 | BIOTISSUE HOLDINGS INC. | $6,660 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-30 | OCULUS, Inc. | $4,500 | Honoraria | Cash or cash equivalent | Keratograph 5M Device, eye diagnostic | 2025 | |
| 2025-10-30 | Dompe US, Inc. | $3,410 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-10-29 | Harrow Eye, LLC | $11,200 | Honoraria | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-29 | Bausch & Lomb Americas Inc. | $2,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-29 | Bausch & Lomb Americas Inc. | $1,200 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-29 | Harrow Eye, LLC | $632 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-29 | Harrow Eye, LLC | $304 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-29 | Harrow Eye, LLC | $270 | Food and Beverage | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-29 | Harrow Eye, LLC | $138 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-29 | Mallinckrodt Hospital Products Inc. | $24 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-10-28 | Dompe US, Inc. | $212 | Travel and Lodging | In-kind items and services | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-10-28 | Dompe US, Inc. | $116 | Food and Beverage | In-kind items and services | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-10-28 | Dompe US, Inc. | $96 | Travel and Lodging | Cash or cash equivalent | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-10-27 | ABBVIE INC. | $600 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-22 | Bausch & Lomb Americas Inc. | $1,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-22 | Bausch & Lomb Americas Inc. | $900 | Consulting Fee | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-22 | Tarsus Pharmaceuticals, Inc. | $625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-10-21 | Harrow Eye, LLC | $11,200 | Honoraria | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-21 | Harrow Eye, LLC | $1,078 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-21 | Harrow Eye, LLC | $261 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-21 | Harrow Eye, LLC | $121 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-21 | Harrow Eye, LLC | $53 | Food and Beverage | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $119 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $110 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-16 | Sight Sciences, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEARCARE SYSTEM Device, Ophthalmology | 2025 | |
| 2025-10-14 | Tarsus Pharmaceuticals, Inc. | $34 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-10-10 | Atlas Ocular, Inc | $9,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-10 | Tarsus Pharmaceuticals, Inc. | $68 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-10 | Glaukos Corporation | $62 | Food and Beverage | Cash or cash equivalent | iStent infinite Device, Ophthalmology | 2025 | |
| 2025-10-09 | Bausch & Lomb Americas Inc. | $3,100 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-09 | Tarsus Pharmaceuticals, Inc. | $149 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-10-09 | Bausch & Lomb Americas Inc. | $53 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-09 | Tarsus Pharmaceuticals, Inc. | $47 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-10-09 | Bausch & Lomb Americas Inc. | $47 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-08 | Bausch & Lomb Americas Inc. | $1,775 | Consulting Fee | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-08 | ABBVIE INC. | $59 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-08 | Harrow Eye, LLC | $38 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-08 | Bausch & Lomb Americas Inc. | $35 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-02 | Bausch & Lomb Americas Inc. | $4,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-01 | Tarsus Pharmaceuticals, Inc. | $312 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-29 | Harrow Eye, LLC | $2,625 | Consulting Fee | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-09-25 | Harrow Eye, LLC | $350 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-25 | Bausch & Lomb Americas Inc. | $22 | Food and Beverage | In-kind items and services | ScoutPro Osmolarity System Device, Ophthalmology | 2025 | |
| 2025-09-24 | Bausch & Lomb Americas Inc. | $209 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-24 | Bausch & Lomb Americas Inc. | $189 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-24 | Bausch & Lomb Americas Inc. | $86 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-21 | Bausch & Lomb Americas Inc. | $25 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-21 | Bausch & Lomb Americas Inc. | $10 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $680 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $99 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $80 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $78 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $12 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $12 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $971 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Tarsus Pharmaceuticals, Inc. | $148 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $30 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-18 | Bausch & Lomb Americas Inc. | $2,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-17 | Harrow Eye, LLC | $42 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-09-16 | Bausch & Lomb Americas Inc. | $9 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-12 | Tarsus Pharmaceuticals, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-09-12 | Tarsus Pharmaceuticals, Inc. | $119 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-09-12 | Tarsus Pharmaceuticals, Inc. | $104 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-09-11 | Sight Sciences, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEARCARE SYSTEM Device, Ophthalmology | 2025 | |
| 2025-09-10 | Tarsus Pharmaceuticals, Inc. | $937 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-10 | Bausch & Lomb Americas Inc. | $625 | Consulting Fee | Cash or cash equivalent | INFUSE Device, Ophthalmology | 2025 | |
| 2025-09-10 | Bausch & Lomb Americas Inc. | $24 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-09 | Mallinckrodt Hospital Products Inc. | $3,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-09-05 | BIOTISSUE HOLDINGS INC. | $3,885 | Consulting Fee | Cash or cash equivalent | AMNIOGRAFT Medical Supply, HUMAN TISSUE PRODUCTS | 2025 | |
| 2025-09-05 | BIOTISSUE HOLDINGS INC. | $66 | Travel and Lodging | Cash or cash equivalent | AMNIOGRAFT Medical Supply, HUMAN TISSUE PRODUCTS | 2025 | |
| 2025-09-05 | Tarsus Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-08-26 | Mallinckrodt Hospital Products Inc. | $38 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $5,500 | Consulting Fee | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Bausch & Lomb Americas Inc. | $4,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $2,000 | Consulting Fee | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $30 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $28 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $21 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $12 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $12 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $6 | Food and Beverage | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-19 | BIOTISSUE HOLDINGS INC. | $150 | Food and Beverage | In-kind items and services | AMNIOGRAFT Medical Supply, HUMAN TISSUE PRODUCTS | 2025 | |
| 2025-08-12 | Bausch & Lomb Americas Inc. | $5,700 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-12 | Bausch & Lomb Americas Inc. | $1,006 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-12 | Tarsus Pharmaceuticals, Inc. | $30 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-08-11 | Bausch & Lomb Americas Inc. | $360 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-08-11 | Bausch & Lomb Americas Inc. | $239 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-08-11 | Bausch & Lomb Americas Inc. | $124 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-08-08 | Mallinckrodt Hospital Products Inc. | $37 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-08-07 | Alcon Vision LLC | $1,000 | Consulting Fee | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-05 | Harrow Eye, LLC | $92 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-08-05 | Alcon Vision LLC | $20 | Food and Beverage | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-04 | Bausch & Lomb Americas Inc. | $24 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2025 | |
| 2025-08-01 | Alcon Vision LLC | $556 | Travel and Lodging | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-01 | Alcon Vision LLC | $397 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-01 | Alcon Vision LLC | $344 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | Alcon Vision LLC | $96 | Travel and Lodging | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-01 | Alcon Vision LLC | $42 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-31 | Bausch & Lomb Americas Inc. | $1,800 | Consulting Fee | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-30 | Tarsus Pharmaceuticals, Inc. | $5,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-07-30 | Tarsus Pharmaceuticals, Inc. | $937 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-30 | Tarsus Pharmaceuticals, Inc. | $769 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-07-30 | Tarsus Pharmaceuticals, Inc. | $87 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-07-24 | OCULUS, Inc. | $4,500 | Honoraria | Cash or cash equivalent | Keratograph 5M Device, eye diagnostic | 2025 | |
| 2025-07-17 | Sight Sciences, Inc. | $4,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEARCARE SYSTEM Device, Ophthalmology | 2025 | |
| 2025-07-17 | Sight Sciences, Inc. | $525 | Travel and Lodging | Cash or cash equivalent | TEARCARE SYSTEM Device, Ophthalmology | 2025 | |
| 2025-07-16 | Glaukos Corporation | $1,500 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-16 | Bausch & Lomb Americas Inc. | $600 | Consulting Fee | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-14 | Bausch & Lomb Americas Inc. | $21 | Food and Beverage | In-kind items and services | ScoutPro Osmolarity System Device, Ophthalmology | 2025 | |
| 2025-07-14 | Bausch & Lomb Americas Inc. | $14 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Bausch & Lomb Americas Inc. | $2,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Alcon Research LLC | $750 | Consulting Fee | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Bausch & Lomb Americas Inc. | $450 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Alcon Vision LLC | $375 | Consulting Fee | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-07-09 | Bausch & Lomb Americas Inc. | $111 | Food and Beverage | In-kind items and services | INFUSE Device, Ophthalmology | 2025 | |
| 2025-07-07 | BIOTISSUE HOLDINGS INC. | $6,660 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-07 | ABBVIE INC. | $450 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-02 | Bausch & Lomb Americas Inc. | $2,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-29 | Harrow Eye, LLC | $3,000 | Consulting Fee | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-06-29 | Harrow Eye, LLC | $736 | Travel and Lodging | Cash or cash equivalent | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-06-26 | Bausch & Lomb Americas Inc. | $3,300 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-26 | Bausch & Lomb Americas Inc. | $114 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2025 | |
| 2025-06-26 | Bausch & Lomb Americas Inc. | $46 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-26 | Bausch & Lomb Americas Inc. | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-26 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-26 | Bausch & Lomb Americas Inc. | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-25 | Dompe US, Inc. | $600 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-25 | Dompe US, Inc. | $600 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-25 | Dompe US, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-25 | Dompe US, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-25 | Dompe US, Inc. | $11 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-25 | Dompe US, Inc. | $11 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-24 | Tarsus Pharmaceuticals, Inc. | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-06-24 | Tarsus Pharmaceuticals, Inc. | $337 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-06-24 | Tarsus Pharmaceuticals, Inc. | $156 | Travel and Lodging | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-06-24 | Tarsus Pharmaceuticals, Inc. | $121 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-06-24 | Mallinckrodt Hospital Products Inc. | $113 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-24 | Mallinckrodt Hospital Products Inc. | $46 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-24 | Mallinckrodt Hospital Products Inc. | $25 | Food and Beverage | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-24 | Dompe US, Inc. | $24 | Food and Beverage | In-kind items and services | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-06-24 | Mallinckrodt Hospital Products Inc. | $12 | Travel and Lodging | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-24 | Mallinckrodt Hospital Products Inc. | $11 | Food and Beverage | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-20 | Tarsus Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-06-18 | Sight Sciences, Inc. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEARCARE SYSTEM Device, Ophthalmology | 2025 | |
| 2025-06-17 | Dompe US, Inc. | $3,410 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-06-17 | Mallinckrodt Hospital Products Inc. | $31 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-16 | RxSight Inc | $5,250 | Consulting Fee | Cash or cash equivalent | RXSIGHT CONTACT LENS Device, OPHTHALMOLOGY | 2025 | |
| 2025-06-12 | Bausch & Lomb Americas Inc. | $2,700 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-11 | Dompe US, Inc. | $859 | Travel and Lodging | Cash or cash equivalent | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-06-11 | Dompe US, Inc. | $120 | Food and Beverage | In-kind items and services | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-06-10 | Mallinckrodt Hospital Products Inc. | $9,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | Mallinckrodt Hospital Products Inc. | $798 | Travel and Lodging | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | Alcon Vision LLC | $250 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-05 | Bausch & Lomb Americas Inc. | $97 | Food and Beverage | In-kind items and services | INFUSE Device, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $45 | Food and Beverage | In-kind items and services | INFUSE Device, Ophthalmology | 2025 |
The latest 200 records of 2,160.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2024-11-27 | Glaukos Corporation | Fisher Scientific | $104 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-11-27 | Glaukos Corporation | Lexitas Pharma Services Inc. | $25 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-11-27 | Glaukos Corporation | Fisher Scientific | $104 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-11-13 | Glaukos Corporation | OCPC | $348 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-10-30 | Glaukos Corporation | Sherpa Clinical Packaging, LLC | $940 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-10-23 | Glaukos Corporation | Amazon.com, Inc. | $33 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-10-02 | Glaukos Corporation | Sherpa Clinical Packaging, LLC | $2,828 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-08-21 | Glaukos Corporation | Amazon.com, Inc. | $8 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2024-06-26 | Glaukos Corporation | Sherpa Clinical Packaging, LLC | $3,372 | A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAG | 2024 |
| 2020-10-21 | Sight Sciences, Inc. | KENTUCKY INSTITUTE FOR EYE HEALTH AND SURGERY PSC | $50,490 | Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in the Treatment of the Sign | 2020 |
| 2020-05-14 | Takeda Pharmaceuticals U.S.A., Inc. | KENTUCKY INSTITUTE FOR EYE HEALTH AND SURGERY PSC | $739 | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF SHP640 (PVP-IOD | 2020 |
| 2020-04-07 | Novartis Pharmaceuticals Corporation | KENTUCKY INSTITUTE FOR EYE HEALTH AND SURGERY PSC | $2,191 | PHASE II STUDY UNR844 1.5% IN SUBJECTS WITH PRESBYOPIA | 2020 |
| 2019-04-29 | Kala Pharmaceuticals, Inc. | KENTUCKY EYE INSTITUTE | $3,000 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-04-25 | Shire North American Group Inc | KENTUCKY INSTITUTE FOR EYE HEALTH AND SURGERY PSC | $1,111 | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF SHP640 PVP-IODI | 2019 |
| 2019-03-27 | Novartis Pharmaceuticals Corporation | KENTUCKY EYE INSTITUTE PSC | $5,402 | PHASE II STUDY UNR844 1.5% IN SUBJECTS WITH PRESBYOPIA | 2019 |
| 2019-01-07 | Sight Sciences, Inc. | Visionary Consultants Inc. | $9,825 | Study of the TearCare System in Dry Eye Disease | 2019 |
| 2019-01-07 | Sight Sciences, Inc. | Visionary Consultants Inc. | $6,260 | Study of the TearCare System in Dry Eye Disease | 2019 |
| 2019-01-07 | Sight Sciences, Inc. | Visionary Consultants Inc. | $1,715 | Study of the TearCare System in Dry Eye Disease | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lexington-Fayette, KY, county Fayette County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Lexington-Fayette, KY | County Fayette County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 323,725 | 323,725 | 4,534,824 |
| Population, 2020 census P1 | 322,570 | 322,570 | 4,505,836 |
| Median age B01002 | 35.3 | 35.3 | 39.1 |
| Under 18 B01001 | 21.0% | 21.0% | 22.6% |
| 65 and over B01001 | 14.7% | 14.7% | 17.3% |
| Households B11001 | 139,715 | 139,715 | 1,814,469 |
| Foreign born B05002 | 11.9% | 11.9% | 4.7% |
| Median household income B19013 | $69,479 | $69,479 | $63,726 |
| Median family income B19113 | $98,855 | $98,855 | $81,505 |
| Per capita income B19301 | $43,790 | $43,790 | $35,821 |
| Poverty rate B17001 | 14.9% | 14.9% | 16.1% |
| Unemployment rate B23025 | 4.9% | 4.9% | 4.9% |
| Civilian labor force B23025 | 180,472 | 180,472 | 2,152,038 |
| Mean commute (minutes) B08013 | 20.9 | 20.9 | 24.0 |
| Bachelor's degree or higher B15003 | 48.3% | 48.3% | 27.6% |
| Housing units B25001 | 148,959 | 148,959 | 2,023,116 |
| Owner-occupied B25003 | 53.8% | 53.8% | 68.3% |
| Renters B25003 | 46.2% | 46.2% | 31.7% |
| Median home value B25077 | $293,500 | $293,500 | $205,600 |
| Median gross rent B25064 | $1,164 | $1,164 | $967 |
| White, not Hispanic B03002 | 66.7% | 66.7% | 81.5% |
| Black B03002 | 14.4% | 14.4% | 7.6% |
| Hispanic or Latino B03002 | 9.5% | 9.5% | 5.0% |
| Asian B03002 | 4.3% | 4.3% | 1.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lexington-Fayette, KY.
Comments